188 related articles for article (PubMed ID: 37341882)
1. Effect of acid sphingomyelinase deficiency in type A Niemann-Pick disease on the transport of therapeutic nanocarriers across the blood-brain barrier.
Loeck M; Placci M; Muro S
Drug Deliv Transl Res; 2023 Dec; 13(12):3077-3093. PubMed ID: 37341882
[TBL] [Abstract][Full Text] [Related]
2. Intertwined mechanisms define transport of anti-ICAM nanocarriers across the endothelium and brain delivery of a therapeutic enzyme.
Manthe RL; Loeck M; Bhowmick T; Solomon M; Muro S
J Control Release; 2020 Aug; 324():181-193. PubMed ID: 32389778
[TBL] [Abstract][Full Text] [Related]
3. ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement.
Garnacho C; Muro S
J Drug Target; 2017; 25(9-10):786-795. PubMed ID: 28665212
[TBL] [Abstract][Full Text] [Related]
4. Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis.
Muro S; Schuchman EH; Muzykantov VR
Mol Ther; 2006 Jan; 13(1):135-41. PubMed ID: 16153895
[TBL] [Abstract][Full Text] [Related]
5. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.
Papademetriou J; Garnacho C; Serrano D; Bhowmick T; Schuchman EH; Muro S
J Inherit Metab Dis; 2013 May; 36(3):467-77. PubMed ID: 22968581
[TBL] [Abstract][Full Text] [Related]
6. Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers.
Garnacho C; Dhami R; Simone E; Dziubla T; Leferovich J; Schuchman EH; Muzykantov V; Muro S
J Pharmacol Exp Ther; 2008 May; 325(2):400-8. PubMed ID: 18287213
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice.
Garnacho C; Dhami R; Solomon M; Schuchman EH; Muro S
Mol Ther; 2017 Jul; 25(7):1686-1696. PubMed ID: 28606376
[TBL] [Abstract][Full Text] [Related]
8. Clathrin-mediated endocytosis is impaired in type A-B Niemann-Pick disease model cells and can be restored by ICAM-1-mediated enzyme replacement.
Rappaport J; Garnacho C; Muro S
Mol Pharm; 2014 Aug; 11(8):2887-95. PubMed ID: 24949999
[TBL] [Abstract][Full Text] [Related]
9. Altered blood-brain barrier transport of nanotherapeutics in lysosomal storage diseases.
Solomon M; Loeck M; Silva-Abreu M; Moscoso R; Bautista R; Vigo M; Muro S
J Control Release; 2022 Sep; 349():1031-1044. PubMed ID: 35901858
[TBL] [Abstract][Full Text] [Related]
10. Altered Clathrin-Independent Endocytosis in Type A Niemann-Pick Disease Cells and Rescue by ICAM-1-Targeted Enzyme Delivery.
Rappaport J; Manthe RL; Garnacho C; Muro S
Mol Pharm; 2015 May; 12(5):1366-76. PubMed ID: 25849869
[TBL] [Abstract][Full Text] [Related]
11. Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier.
Hsu J; Rappaport J; Muro S
Pharm Res; 2014 Jul; 31(7):1855-66. PubMed ID: 24558007
[TBL] [Abstract][Full Text] [Related]
12. In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors.
Papademetriou IT; Garnacho C; Schuchman EH; Muro S
Biomaterials; 2013 Apr; 34(13):3459-66. PubMed ID: 23398883
[TBL] [Abstract][Full Text] [Related]
13. Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.
Hsu J; Northrup L; Bhowmick T; Muro S
Nanomedicine; 2012 Jul; 8(5):731-9. PubMed ID: 21906578
[TBL] [Abstract][Full Text] [Related]
14. Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance.
Kim J; Sinha S; Solomon M; Perez-Herrero E; Hsu J; Tsinas Z; Muro S
Biomaterials; 2017 Dec; 147():14-25. PubMed ID: 28923682
[TBL] [Abstract][Full Text] [Related]
15. Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A.
Long Y; Xu M; Li R; Dai S; Beers J; Chen G; Soheilian F; Baxa U; Wang M; Marugan JJ; Muro S; Li Z; Brady R; Zheng W
Stem Cells Transl Med; 2016 Dec; 5(12):1644-1655. PubMed ID: 27484861
[TBL] [Abstract][Full Text] [Related]
16. Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes.
Papademetriou I; Tsinas Z; Hsu J; Muro S
J Control Release; 2014 Aug; 188():87-98. PubMed ID: 24933603
[TBL] [Abstract][Full Text] [Related]
17. A fibrinogen-derived peptide provides intercellular adhesion molecule-1-specific targeting and intraendothelial transport of polymer nanocarriers in human cell cultures and mice.
Garnacho C; Serrano D; Muro S
J Pharmacol Exp Ther; 2012 Mar; 340(3):638-47. PubMed ID: 22160267
[TBL] [Abstract][Full Text] [Related]
18. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
Hsu J; Serrano D; Bhowmick T; Kumar K; Shen Y; Kuo YC; Garnacho C; Muro S
J Control Release; 2011 Feb; 149(3):323-31. PubMed ID: 21047542
[TBL] [Abstract][Full Text] [Related]
19. A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders.
Rappaport J; Manthe RL; Solomon M; Garnacho C; Muro S
Mol Pharm; 2016 Feb; 13(2):357-368. PubMed ID: 26702793
[TBL] [Abstract][Full Text] [Related]
20. Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1.
Bhowmick T; Berk E; Cui X; Muzykantov VR; Muro S
J Control Release; 2012 Feb; 157(3):485-92. PubMed ID: 21951807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
